MAUNA KEA TECHNOLOGIES (ALMKT) AI Stock Analysis

• Market Cap: €8.33M
• Dividend Yield: N/A
• Average Volume (3M): 199.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.81
• Revenue Growth: -26.96%
• EPS Growth: -313.86%
• Country: FR
• Employees: 65
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Devices
• EPS (TTM): -0.08
• Shares Outstanding: 79,380,500
• 10 Day Avg. Volume: 58,329
• 30 Day Avg. Volume: 199,529
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: €0.00 ▼(-100.00% Downside)

The overall stock score reflects significant financial challenges and bearish technical indicators. The company's financial instability, marked by declining revenues and negative equity, is the most critical factor impacting the score. Technical analysis suggests a bearish trend, adding to the negative outlook. Valuation concerns due to the negative P/E ratio further weigh down the score.

MAUNA KEA TECHNOLOGIES Business Overview & Revenue Model

Company Description

Mauna Kea Technologies SA, a medical device company, manufactures and sells medical devices in Europe and internationally. It offers range of medical devices in gastroenterology, pulmonology, and urology areas. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform which enables physicians to monitor progression of disease over time, assess point-in-time reactions, classify indeterminate areas, and guide surgical interventions. The company was incorporated in 2000 and is headquartered in Paris, France.

How the Company Makes Money

MAUNA KEA TECHNOLOGIES generates revenue through the sale of its proprietary imaging systems, consumables, and maintenance services. The primary revenue stream comes from the sale of the Cellvizio systems and associated disposable devices used in procedures. Additionally, the company earns recurring revenue from service contracts and ongoing maintenance for its imaging systems. Significant partnerships with healthcare institutions and distributors also contribute to its earnings by expanding market reach and facilitating product adoption in clinical settings. Furthermore, the company may engage in collaborations and licensing agreements that could enhance its revenue potential.

MAUNA KEA TECHNOLOGIES Financial Statement Overview

Summary

Mauna Kea Technologies is facing significant financial difficulties with declining revenues, persistent losses, and high leverage. The negative net profit margin of -135.9% and negative equity further indicate financial instability, despite a strong gross profit margin.

Income Statement

Mauna Kea Technologies faced significant challenges with declining revenue and profitability. The revenue dropped by 30.6% from 2023 to 2024, and the company experienced negative net income, leading to a net profit margin of -135.9% in 2024. The gross profit margin was relatively strong at 84.1% but was insufficient to prevent substantial operating losses.

Balance Sheet

The balance sheet reveals a troubling debt-to-equity ratio due to negative equity, indicating high financial risk and leverage. With total liabilities exceeding total assets, the company is in a negative equity position, which may pose significant challenges in sustaining operations without restructuring its finances.

Cash Flow

Cash flow statements show negative operating and free cash flows, with a minor improvement in free cash flow compared to the previous year. However, the company remains in a precarious cash position, exacerbated by significant negative operating cash flows relative to net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.66M	11.03M	8.11M	7.70M	7.25M
Gross Profit	6.44M	8.93M	5.47M	5.71M	4.38M
EBITDA	-7.97M	-1.46M	-9.93M	-11.23M	-11.43M
Net Income	-10.40M	-3.73M	-11.18M	-13.45M	-12.79M
Balance Sheet
Total Assets	16.25M	22.94M	19.79M	24.75M	20.61M
Cash, Cash Equivalents and Short-Term Investments	1.92M	7.91M	3.15M	11.89M	8.66M
Total Debt	31.93M	29.77M	29.20M	28.70M	26.96M
Total Liabilities	40.63M	40.21M	39.72M	35.08M	32.69M
Stockholders Equity	-24.39M	-17.28M	-19.92M	-10.33M	-12.08M
Cash Flow
Free Cash Flow	-6.54M	-1.14M	-8.97M	-11.37M	-9.07M
Operating Cash Flow	-6.32M	-753.00K	-8.83M	-10.27M	-7.99M
Investing Cash Flow	-149.00K	-354.00K	-57.00K	-1.14M	-999.00K
Financing Cash Flow	483.00K	5.96M	109.00K	14.65M	7.68M

MAUNA KEA TECHNOLOGIES Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMKT, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.50 is Neutral, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMKT.

MAUNA KEA TECHNOLOGIES Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
ALMKT	45 Neutral	€8.33M	―		―	-26.96%	-313.86%
TCLIF	―	$44.91M	―	-199.44%	―	―	―
DMS1	―	€29.19M	―	-22.84%	―	―	―
9W8	―	€21.23M	―	-16.43%	―	―	―
61R	―	€10.99M	―		―	―	―
4ZG	―	€87.75M	―		―	―	―